ACTUALIZED INFORMATION ON THE USE OF LEVOCETIRIZINE IN URTICARIA



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Urticaria is a widespread disease with various phenotypes, duration and severity of the course, a pronounced effect on the quality of life. Despite the heterogeneity of the disease, a huge variety of provoking triggers, the activation of mast cells is still considered the key link in pathogenesis, and therefore antihistamines of the 2nd generation remain effective and safe drugs for treatment of urticaria. The process of improving antihistamines actively continues, one of the directions is the search for molecules based on the release of more active and safe enantiomers from already known drugs (example: levocetirizine from cetirizine). Information on levocetirizine, the efficacy and safety of which in the treatment of urticaria in both adults and children, has been demonstrated in a number of well-planned randomized controlled clinical trials, as well as in various preclinical studies, due to the accumulation of new data, the advent of generic drugs, and also a new scale for assessing the quality of clinical data in the GRADE system needs to be updated. The present review is devoted to solving this problem.

Full Text

Restricted Access

About the authors

N G Astafieva

Federal state budgetary educational institution of higher professional education «Saratov state medical University named after V.I. Razumovsky» Ministry of health of the Russian Federation

Email: astang@mail.ru
112, Bolshaya Kazachya, 410012, Saratov, Russia

D Y Kobzev

Leeds Trinity University

Horsforth, Leeds LS18 5HD, UK

I V Gamova

Federal state budgetary educational institution of higher professional education «Saratov state medical University named after V.I. Razumovsky» Ministry of health of the Russian Federation

112, Bolshaya Kazachya, 410012, Saratov, Russia

I A Perfilova

Federal state budgetary educational institution of higher professional education «Saratov state medical University named after V.I. Razumovsky» Ministry of health of the Russian Federation

112, Bolshaya Kazachya, 410012, Saratov, Russia

E N Udovichenko

Federal state budgetary educational institution of higher professional education «Saratov state medical University named after V.I. Razumovsky» Ministry of health of the Russian Federation

112, Bolshaya Kazachya, 410012, Saratov, Russia

I E Mikhaylova

Federal state budgetary educational institution of higher professional education «Saratov state medical University named after V.I. Razumovsky» Ministry of health of the Russian Federation

112, Bolshaya Kazachya, 410012, Saratov, Russia

L V Skuchaeva

Federal state budgetary educational institution of higher professional education «Saratov state medical University named after V.I. Razumovsky» Ministry of health of the Russian Federation

112, Bolshaya Kazachya, 410012, Saratov, Russia

References

  1. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzo-za Z, Canonica GW et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014; 69: 868-887.
  2. Magerl M, Altrichter S, Borzova E, Gimenez-Arnau A, Grattan CEH, Lawlor F et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016; 71: 780-802.
  3. Колхир ПВ. Крапивница и ангиоотек. М. Практическая медицина, 2012: 363. ISBN 5-98811-228-5.
  4. Горячкина ЛА, Ненашева НМ, Борзова ЕЮ. Крапивница. Новости медицины и фармации, 2010; (322): 10-22.
  5. Данилычева ИВ, Ильина НИ, Лусс ЛВ, Феденко ЕС, Шульженко АЕ. Федеральные клинические рекомендации по диагностике и лечению крапивницы. РАЖ. 2016; (1): 38-46.
  6. Соколов ВИ. Введение в теоретическую стереохимию, М., 1982.
  7. Bonner WA. Origins of Chiral Homogeneity in Nature. Topics in Stereochemistry. 2007; 18: 1-96. doi: 10.1002/9780470147276 ch1.
  8. Pierson WE. Cetirizine: a unique second-generation antihistamine for treatment of rhinitis and chronic urticaria. Clin Ther. 1991; 13: 92-99.
  9. Гущин ИС. Разнообразие противоаллергического действия цетиризина. Росс Аллергол Журн. 2006; (4): 33-44
  10. Клиническая аллергология и иммунология: руководство для практикующих врачей под ред. Л.А. Горячкиной и К.П. Кашкина. М., «Миклош». 2009: 432.
  11. Gillard M, Van Der Perren C, Moguilevsky N, Massingham R, Chatelain P. Binding characteristics of cetirizine and levocetirizine to human H1-histamine receptors: contribution of Lys(191) and Thr(194). Mol Pharmacol. 2002; 61(2): 391-399.
  12. Day JH, Ellis AK, Rafeiro E. Levocetirizine: a new selective H1 receptor antagonist for use in allergic disorders. Drugs Today (Barc.). 2004; 40: 415-421.
  13. Benedetti MS, Plisnier M, Kaise J, Maier L, Baltes E, Arendt C et al. Absorption, distribution, metabolism and excretion of [14C] levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. 2001; 57: 571-582.
  14. Mansfield P, Henry D, Tonkin A. Single-enantiomer drugs: elegant science, disappointing effects. Clin Pharmacokinet. 2004; 43: 287-290.
  15. Hutt AJ, Valentova J. The chiral switch: the development of single enantiomer drugs from racemates. Acta Faccult Phar Univ Comenianae. 2003; 50: 7-23.
  16. Canadian Task Force on the Periodic Health Examination. http://www.answers.com/topic/canadian-task-force-on-preventive-health-care.
  17. Kapp A, Demarteau N. Cost effectiveness of levocetirizine in chronic idiopathic urticaria: a pooled analysis of two randomised controlled trials. Clin Drug Investig. 2006; 26: 1-11.
  18. Sharma M, Bennett C, Cohen SN, Carter B. H1-antihista-mines for chronic spontaneous urticaria. Cochrane Database Syst Rev. 2014; 14: CD006137. doi: 10.1002/14651858.CD006137.
  19. Nettis E, Colanardi MC, Barra L, Ferrannini A, Vacca A, Tursi A. Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2006; 154: 533-538.
  20. Potter PC, Kapp A, Maurer M, Guillet G, Jian AM, Hauptmann P, Finlay AY. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009; 64: 596-604. doi: 10.1111/j.1398-9995.2008.01893.
  21. Simons FE. Early Prevention of Asthma in Atopic Children Study Group. H1-antihistamine treatment in young atopic children: effect on urticaria. Ann Allergy Asthma Immunol. 2007; 99: 261-266.
  22. Grading of Recommendations Assessment, Development and Evaluation. http://www.gradeworkinggroup.org.
  23. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y Flottorp S et al. Grading quality of evidence and strength of recommendations. GRADE Working Group. BMJ. 2004; 328: 1490.
  24. Guyatt GH, Cook DJ, Jaeschke R, Pauker SG, Schünemann HJ. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 123-131. doi: 10.1378/chest.08-0654.
  25. Brozek JL, Bousquet J, Agache I. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140: 950-958. doi: 10.1016/j.jaci.2017.03.050.
  26. Гущин ИС. Перспективы совершенствования противоаллергического действия Hj-антигистаминных препаратов. Лечащий Врач. 2009; (5): 1-4.
  27. Church DS, Church MK. Pharmacology of Antihistamines. World Allergy Organ J. 2011; 4: 22-27.
  28. Simons FE, Simons KJ. Histamine and Hj-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2001; 128: 1139-1150.e4. doi: 10.1016/j.jaci.2011.09.005.
  29. Leurs R, Church M, Taglialatela M. Hj-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002; 32: 489-498.
  30. Holgate ST, Canonica GW, Simons FER. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003; 33: 1305-1324.
  31. Walsh GM. A review of the role of levocetirizine as an effective therapy for allergic disease. Expert Opin Pharmacother. 2008; 9: 859-867.
  32. Denham KJ, Boutsiouki P, Clough GF, Church MK. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res. 2000; 52: 424-427.
  33. Purohit A, Melac M, Pauli G, Frossard N. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol. 2003; 56: 388-394.
  34. Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002; 88: 190-197.
  35. Liu H, Farley JM. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacology. 2005; 5: 1-10.
  36. Gillard M, Christophe B, Wels B, Peck M, Massingham R, Chatelain P. H1 antagonists: receptor affinity versus selectivity. Inflamm Res. 2003; 52: 49-50.
  37. Трусова ОВ, Коростовцев ДС. Левоцетиризин (Ксизал). Характеристика препарата и опыт клинического применения. Аллергология. 2006; (2): 25-31. [Trusova OV, Korostovcev DS. Levocetirizin (Ksizal). Harakteristika preparata i opyt klinicheskogo primeneniya. Allergologiya. 2006; (2): 25-31 (In Russ.)].
  38. Jauregui I, Ferrer M, Montoro J, Davila I, Bartra J, A del Cu-villo et al. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol. 2007; 17: 41-52.
  39. Колхир ПБ. Доказательная аллергология-иммунология. М., Практическая медицина. 2010: 528.
  40. Фомина ДС, Горячкина ЛА. Выбор антигистаминного препарата с позиции доказательной медицины. Эффективная фармакотерапия. Аллергология и иммунология. 2012; (1): 18-24.
  41. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. World Health Organization; GA2LEN; AllerGen. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008; 63: 8-160.
  42. Kanei A, Asano K, Kanai K, Furuta A, Sasaki K, Suzaki H. Inhibitory action of levocetirizine on the production of eosinophil chemoattractants RANTES and eotaxin in vitro and in vivo. In Vivo. 2014; 28: 657-666.
  43. Komatsuzaki T, Suzaki I, Hirano K, Kanai K, Asano K, Suzaki H. Suppression of osteopontin functions by levocetirizine, a histamine H1 receptor antagonist, in vitro. Biomed Res Int. 2013; 2013: 735835. doi: 10.1155/2013/735835.
  44. Hasala H, Janka-Junttila M, Moilanen E, Kankaanranta H. Levocitirizini and cytokine production and apoptosis of human eosinophilis. Allergy Asthma Proc. 2007; 28: 582-591.
  45. Sharma M, Bennett C, Cohen SN, Carter B. Hj-antihista-mines for chronic spontaneous urticaria. Cochrane Database of Systematic Reviews. 2014, Issue 11. Art. No.: CD006137. doi: 10.1002/14651858.CD006137.pub2.
  46. Bocşan CI, Bujor AI, Miron N, Vesa ŞC, Deleanu D, Buzoianu AD. In vivo anti-inflammatory effect of Hj-antihistamines in allergic rhinitis. Balkan Med J. 2015; 32: 352-358.
  47. Goyal V, Gupta A, Gupta O, Lal D, Gill M. Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. Journal of Clinical and Diagnostic Research. 2017; 11: 6-9.
  48. Munoz-Cano R, Ainsua-Enrich E, Torres-Atencio I, Martin M, Sánchez-Lopez J, Bartra et al. Effects of Rupatadine on Platelet-Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). J Investig Allergol Clin Immunol. 2017; 27: 161-168. doi: 10.18176/jiaci.0117.
  49. Shih MY, Hsu JY, Weng YS, Fu LS. Influence of cetirizine and levocetirizine on two cytokines secretion in human airwy epithelial cells. Allergy Asthma Proc. 2008; 29: 480-485.
  50. Simons FE, Simons KJ. Clinical pharmacology of H1-anti-histamines. Clin Allergy Immunol. 2002; 17: 141-178.
  51. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol. 2001; 15: 897-918.
  52. Graziano FM, Cook EB, Stahl JL. Antihistamines and epithelial cells. Allergy Asthma Proc. 2000; 21: 129-140. PMID: 10892513.
  53. Ashenager MS, Grgela T, Aragane Y, Kawada A. Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines. J Investig Allergol Clin Immunol. 2007; 1: 20-26.
  54. Devalia JL, De Vos C, Hanotte F, Baltes E. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy. 2001; 56: 50-57.
  55. Гущин ИС. Полифункциональные противоаллергические возможности антагониста Н1рецепторов - левоцетиризина. Росс Аллергол Журн. 2014; (2): 11-24. [Gushchin IS. Polifunkcional’nye protivoallergicheskie vozmozhnosti an-tagonista Nj-receptorov - levocetirizina. Russian Journal of allergy. 2014; 2: 11-24 (In Russ.)].
  56. Mahmoud F, Arifhodzic N, Haines D, Novotney L. Levo-cetirizine modulates lymphocyte activation in patients with allergic rhinitis. J Pharmacol Sci. 2008; 108: 149-156.
  57. Marcucci F, Sensi LG, Abate P, Allocca G, Ugolini E, Di Cara G et al. Anti-inflammatory activity and clinical efficacy of a 3-month levocetirizine therapy in mite-allergic children. Inflamm Allergy Drug Targets. 2011; 10: 32-38.
  58. Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, Allen M, Marseglia GL. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005; 5: 1800-1808.
  59. Barniol C, Dehours E, Mallet J, Houze-Cerfon CH, Lau-que D, Charpentier S. Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial. Ann Emerg Med. 2017; 2: 196-644. doi: 10.1016/j.anne-mergmed.2017.03.006.
  60. Chen C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem. 2008; 15: 2173-2191.
  61. Карева ЕН. Выбор антигистаминного препарата: взгляд фармаколога. РМЖ «Медицинское обозрение». 2016; 12: 811-816
  62. Hu Y, Sieck DE, Hsu WH. Why are second-generation Hj-antihistamines minimally sedating? Eur J Pharmacol. 2015; 765: 100-106.
  63. Inami A, Matsuda R, Grobosch T, Komamura H, Takeda K, Yamada Y et al. A simulated car-driving study on the effects of acute administration of levocetirizine, fexofenadine, and diphenhydramine in healthy Japanese volunteers. Hum Psychopharmacol Clin Exp. 2016; 31: 167-177. doi: 10.1002/hup.
  64. Paśko P, Rodacki T, Domagala-Rodacka R, Palimonka K, Marcinkowska M, Owczarek D. Second generation Hj-antihistamines interaction with food and alcohol-A systematic review. Biomed Pharmacother. 2017; 93: 27-39. DOI: 10.1016/j. biopha.2017.06.008.
  65. Snidvongs К, Seresirikachorn К, Khattiyawittayakun L, Chitsuthipakorn W. Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Drugs. 2017; 77: 175-186. doi: 10.1007/s40265-016-0682-0).
  66. Klimek L. Levocetirizine: from scientific evidence to a potent modern-day treatment of today’s allergic patients. Drugs Today (Barc.). 2009; 45: 213-225.
  67. FDA/CDER SBIA Chronicles. Drugs in Pregnancy and Lactation: Improved Benefit-Risk Information. January 22, 2015. Accessed July 25, 2016 at http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM431132.pdf.
  68. Gonzalez-Estrada A, Geraci SA. Allergy Medications During Pregnancy. Am J Med Sci. 2016; 352: 326-31. doi: 10.1016/j.amjms.2016.05.030.
  69. Newton ER, Hale TW. Drugs in Breast Milk. Clin Obstet Gynecol. 2015; 58: 868-884. doi: 10.1097/GRF.0000000000000142.
  70. Астафьева НГ, Гамова ИВ, Удовиченко ЕИ, Перфилова ИА. Левоцетиризин: современные аспекты применения при аллергических заболеваниях с точки зрения доказательной медицины. Лечащий врач. 2010; (5): 62-68.
  71. Абатуров АЕ, Борисова ТП. Дифференцированный подход к назначению антигистаминных препаратов при аллергических заболеваниях в детском возрасте. Здоровье ребенка. 2016; (5): 121-127. DOI: http://dx.doi.org/10.22141/2224-0551.5.73.2016.78309
  72. Sharma VK, Gupta V, Pathak M, Ramam M. An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose. J Dermatolog Treat. 2017; 25: 1-5. doi: 10.1080/09546634.2016.1246705.
  73. Аллергология. Федеральные клинические рекомендации. Главные редакторы: акад. РАН Р.М. Хаитов, проф. Н.И. Ильина. М., «Фармарус Принт Медиа». 2014: 126.
  74. Popov TA. Challenges in the management of chronic urticaria. World Allergy Organ J. 2011; 4: 28-31.
  75. Bachert C, Maspero J. Efficacy of second-generation antihistamines in patients with allergic rhinitis and comorbid asthma. 2011; 48: 965-973. doi: 10.3109/02770903.2011.616616.
  76. Kim JH, Kwon HJ, Jang YJ. Levocetirizine inhibits rhinovirusinduced up-regulation of fibrogenic and angiogenic factors in nasal polyp fibroblasts. Am J Rhinol Allergy. 2011; 25: 416-420. doi: 10.2500/ajra.2011.25.3684.
  77. Jang YJ, Wang JH, Kim JS, Kwon HJ, Yeo NK, Lee BJ. Levocetirizine inhibits rhinovirus-induced ICAM-1 and cytokine expression and viral replication in airway epithelial cells. Antiviral Res. 2009; 81: 226-233. doi: 10.1016/j.antiviral.2008.12.001.
  78. De Sutter AI, Saraswat A, van Driel ML. Antihistamines for the common cold. Cochrane Database Syst Rev. 2015; 11: CD009345. doi: 10.1002/14651858.CD009345.pub2.
  79. Al-Kasmi B, Alsirawan MB, Bashimam M, El-Zein H. Mechanical microencapsulation: The best technique in taste masking for the manufacturing scale - Effect of polymer encapsulation on drug targeting. J Control Release. 2017; 260: 134-141. doi: 10.1016/j.jconrel.2017.06.002.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2017



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies